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INTRODUCTION 
             Pleural effusion is a very common clinical presentation of diseases. A 
correct diagnosis of the underlying disease is essential for the management of 
pleural effusion. A limited number of diseases cause Transudative Pleural 
Effusion, whereas exudative effusions require more extensive diagnostic 
investigations. Therefore, the first step is to classify them as transudates or 
exudates, even if this differentiation does not contribute to the etiological 
diagnosis.  
Many criteria have been used to distinguish them, but none of them have 
been found to be satisfactory. Light’s criteria is the most commonly used 
method  
 
 The criteria is one or more of the following to diagnose exudates. 
1. Pleural fluid protein / Serum protein>0.5 
2. Pleural fluid LDH/ Serum LDH >0.6  
3. Pleural fluid LDH more than 2/3rd of the upper limit of serum 
LDH. 
It was found that even Light’s criteria misclassified a large number of 
effusions - 25% of transudates as exudates. 
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Hence, there is a need to probe into new parameters which will prove to 
be superior or supportive to the various investigations available at present. 
Many other biochemical markers like bilirubin, cholesterol, alkaline 
phosphatase etc. can be taken into consideration. 
 
Hence, this study is done to evaluate the efficacy of Total Pleural fluid 
Alkaline Phosphatase (ALP) and its ratio to Serum Alkaline Phosphatase levels 
in classifying the Pleural Effusion as Exudate or Transudate and its correlation 
with Light’s criteria. 
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AIMS AND OBJECTIVES  
 
To evaluate the advantages of Total Pleural fluid Alkaline 
Phosphatase(ALP) and its ratio to Serum Alkaline Phosphatase levels in 
classifying Pleural Effusions as Exudates or Transudates. 
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REVIEW OF LITERATURE 
 
Definition 
Pleural effusion is defined as the abnormal accumulation of pleural fluid 
within the pleural cavity. Crucial feature of the breathing apparatus is the 
pleural space. “This is a potential space between the parietal pleura and the 
visceral pleura.It is the coupling system between the lung and the chest wall.” 
 
ANATOMY OF PLEURA  
The lung parenchyma, the diaphragm, the mediastinum and the rib cage 
are covered by a serous membrane called the Pleura. Pleurais divided into 
visceral pleura and parietal pleura. Both these layers meet at the lung root. 
 
Visceral pleura 
“It covers the lung parenchyma in its points of contact with the 
diaphragm, the mediastinum and the chest wall and also in the inter-lobar 
fissures” 
Parietal pleura 
“It lines the inside of the thoracic cavities.  
It is subdivided on the basis of intra-thoracic structures that it lines into  
1. Costal parietal pleura 
2. Mediastinal parietal pleura 
3. Diaphragmatic parietal pleura”. 
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Pulmonary ligament 
This is a thin double fold of pleura formed due to the downward 
extension of the pleura, posterior to the lung root. 
 
Pleural space 
This is a potential space present between the visceral and parietal pleura. 
 
Pleural fluid 
“This is a thin film of fluid normally present in between the visceral 
pleura and parietal pleura i.e., pleural space” 
Functions of pleural fluid: It acts as a lubricant. During the respiratory 
movements the pleural fluid facilitates the visceral pleura which is covering the 
lung to slide along the parietal pleura which lines the thoracic cavity. 
 
HISTOLOGY OF PLEURA 
“Parietal pleura and visceral pleura are composed of two layers, namely 
the mesothelium and the connective tissue.” 
 
Functions of Connective tissue layer 
1. Contributes to elastic recoil of lung and helps in expelling air from the 
lung 
2. Restricts the inflatable volume of lung and thereby protects the lung. 
 
 
6 
 
Functions of Mesothelial cells 
It forms a monolayer of pavement like cells lining the pleural surfaces. 
1. Movement and transport of particulate matter and fluid across the pleural 
surfaces. 
2. Migration of leucocytes in response to inflammation. 
3. Synthesis of cytokines, growth factors, extracellular matrix proteins. 
4. Antigen presentation and transformation to myofibroblasts. 
 
Blood supply 
 “Parietal pleura receives blood supply from systemic capillaries 
namelyintercostal artery,pericardiophrenic artery, superior phrenic and 
musculophrenicartery  and drained by intercostal veins and phrenic veins. 
Visceral pleura: Pulmonary circulation supplies thin pleura and Bronchial 
arteries supply thick pleura. Venous drainage is through the pulmonary veins.” 
 
Lymphatic drainage 
Lymphatic plexus in the parietal pleura drains into intercostal, 
mediastinal, tracheobronchial , parasternal and phrenic nodes. 
In the parietal pleura the lymphatic vessels are in communication with the 
stomas, the diameter of whichranges between 2 to 6 microns. The main pathway 
for the elimination of particulate matter is the stomas with lacuna and lymphatic 
vessels. 
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In the visceral pleura there are abundant lymphatic vessels which join bronchial 
lymph vessels. 
 
Nerve supply 
Intercostal nerves supply the costal and peripheral part of diaphragmatic 
pleura. So the pain sensation due to inflammation of this part of pleura is 
perceived in the chest wall. 
Phrenic nerve supplies the central part of diaphragmatic pleura. So when 
this part of pleura is irritated or inflamed the pain is felt in the ipsilateral 
shoulder.   
 
PHYSIOLOGY OF PLEURA  
Formation of the Pleural Fluid: 
“Pleural fluid can originate in the  
 pleural capillaries 
 intra-thoracic lymphatics 
 intrathoracic blood vessels 
 peritoneal cavity or 
 interstitial spaces of the lung.” 
 
Pleural Capillaries 
The movement of fluid between the pleural capillaries and the pleural 
space obeys the Starling’s law of transcapillary exchange. 
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Hydrostatic pressure 
In the parietal pleura, the hydrostatic pressure is approximately 30 cm 
H2O,but  the pleural pressure is approximately -5 cm H2O. The net hydrostatic 
pressure is therefore 30 - (-5) = 35 cm H2O.This pressure favours the movement 
of fluid from the capillaries in the parietal pleura to the pleural space.   
 
Oncotic pressure 
The hydrostatic pressure gradient is opposed by oncotic pressure gradient. 
Plasma oncotic pressure is approximately 34 cm H2O.  
Normally, the pleural fluid has an oncotic pressure of approximately 5 cm 
H2O, as it contains a small amount of protein .The  net oncotic pressure gradient 
is  34 - 5 = 29 cm H2O. Thus, the net gradient is 35 - 29 = 6 cm H2O. It favours 
the movement of fluid to the pleural space from the capillaries present in the 
parietal pleura. 
The net gradient for fluid movement across the visceral pleura in humans 
is probably close to zero, which has not been demonstrated. The pressure in the 
parietal pleural capillaries is approximately 6 cm H2O more than that in the 
visceral pleural capillaries.  
This is because capillaries in the visceral pleural are drained by the 
pulmonary veins. This is the only pressure that differs from the pressure 
affecting fluid movement across the parietal pleura. The net gradient for the 
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parietal pleura is 6 cm H2O. So the net gradient is approximately zero for fluid 
movement across the visceral pleura. 
 The capillaries in the visceral pleura are much farther from the pleural 
space when compared to the capillaries in the parietal pleura. Hence the 
filtration coefficient (Lp) for the visceral pleura is substantially less than that for 
the parietal pleura. 
The fluid formation is more across the parietal pleura over the ribs than 
the pleura over the intercostal spaces,. Also fluid formation was more over the 
caudal ribs than over the cranial ribs.  But in contrast, pleural liquid absorption 
was more primarily in the parietal pleura adjacent to the intercostal space rather 
than that overlying the ribs. The formation of pleural fluid was more, if the 
breathing frequency was increased. 
 
Interstitial Origin 
“It has been demonstrated that the interstitial spaces of the lungs is the 
origin of much of the fluid that enters the pleural space. Pleural fluid 
accumulates if there is either high-pressure or high-permeability pulmonary 
edema. The elevation in the wedge pressure is directly related to the amount of 
pleural fluid formed. But increased pleural fluid accumulation occur only after 
the development of pulmonary edema. The origin of the pleural effusion is 
probably the pulmonary interstitial space in patients with congestive heart 
failure,.” 
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“It is likely that in many conditions associated with lung injury, such as 
lung transplantation and pulmonary embolisation, the origin of the pleural fluid 
is also the interstitial spaces of the lung. 
It has been shown that the subpleural interstitial pressure increases with 
increasing levels of interstitial fluid. Even though the visceral pleura is thin, the 
barrier to the movement of fluid across the visceral pleura appears to be weak. 
Hence, once there is increase in subpleural interstitial pressure, the fluid will 
enter to the pleural space through the visceral pleura.” 
 
Peritoneal Cavity 
“If there is free fluid in the peritoneal cavity, pleural fluid accumulation 
can occur. Peritoneal fluid enters the pleural space through the openings in the 
diaphragm. Since the pressure in the pleural cavity is less than the pressure in 
the peritoneal cavity the fluid will flow from the peritoneal space to the pleural 
space. In conditions like hepatic hydrothorax, Meigs' syndrome, and peritoneal 
dialysis, the peritoneal cavity is the origin of the pleuralfluid.” 
 
Thoracic Duct or Blood Vessel Disruption 
If there is disruption of thoracic duct, there is accumulation of lymph in the 
pleural space. This will produce a chylothorax. The rate of fluid accumulation 
can be more than 1,000 mL/day in chylothorax. 
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Origin of Normal Pleural Fluid 
Pleural fluid is formed from the parietal pleural capillaries. The amount 
of pleural fluid formed daily is approximately 15 mL in a 50-kg individual. 
Since the protein level in the interstitial spaces is normally approximately 4.5 
g/dL, and the protein level in normal pleural fluid is only approximately 1 to 1.5 
g/dL, the origin of the fluid does not appear to be the interstitial spaces of the 
lung. Pleural fluid with lower protein levels are produced by higher vascular 
pressures. Evans blue dyed albumin studies with rabbits have demonstrated that 
most fluid originates in the parietal pleura over the ribs. 
 
Pleural Fluid Absorption 
Lymphatic Clearance 
The lack of fluid accumulation in normal individuals is due to the 
clearance of fluid through the pleural lymphatics. The pleural space 
communicates with the lymphatic vessels in the parietal pleura via stomas in the 
parietal pleura. Visceral pleura lacks such stomas. The lymphatics in the parietal 
pleura removes proteins, cells and all other particulate matter from the pleural 
space. The carbon particles exit the pleural space through the stomas where the 
mesothelial cells are small and not flattened. Increased levels of nitric oxide in 
the pleural space cause increase in diameter of the stomas. 
In a 60-kg individual the lymphatic drainage from each pleural space is on the 
order of 20 mL/hr or 500 mL/day.  
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Once the volume of the pleural liquid exceeds a particular threshold, the 
lymphatics operate at maximum capacity.  
 
Clearance through Capillaries in Visceral Pleura 
 Until the mid-1980s, it was thought that the capillaries in the visceral 
pleura in humans were the primary route for the exit of fluid from the pleural 
space. 
Through the lymphatics in the parietal pleura almost all the pleural fluid 
is removed. Several hundred millilitres of water probably traverse the pleural 
membranes each day. The net movement is of only a few millilitres as the 
osmolarity is nearly identical on each side of the membrane.  
 
Alternative Mechanisms for Pleural Fluid Removal 
Transcytosis plays a role in the removal of protein from the pleural space. 
Only 29% of the overall removal of albumin occurred through the stoma with 
small hydrothoraces, while 64% of the albumin from large hydrothoraces was 
removed through the stoma. 
 
Pathogenesis of Pleural Effusions 
Pleural effusion occurs whenever “the rate of pleural fluid formation 
exceeds the rate of pleural fluid absorption.“ 
“Normally, a small amount (0.01 mL/kg/hour) of fluid constantly enters 
the pleural space from the capillaries in the parietal pleura. The lymphatics in 
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the parietal pleura remove almost all of this fluid. Lymphatics have a capacity to 
remove at least 0.20 mL/kg/hour. The lymphatics remove the fluid exceeding 
the normal rate of fluid formation by a factor of 20.”  
 
GENERAL CAUSES OF PLEURAL EFFUSION  
A. Increased pleural fluid formation : 
1. “Increased interstitial fluid in lungs  
 - Left ventricular failure 
- Pneumonia 
- Pulmonary embolism 
2. Decreased pleural pressure 
- Lung atelectasis  
- Elastic recoil of lung is increased 
3. Increased permeability of pleural capillaries  
 -  Pleural inflammation 
 - Elevated vascular endothelial growth factor (VEGF) levels 
4. Increased levels of protein in the pleural fluid 
5. Increased intravascular pressure in pleura 
 -  Right or left ventricular pressure 
 - Superior vena cava syndrome 
6. Disruption of thoracic blood vessels 
7. Thoracic duct disruption 
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8. Increased fluid in the peritoneal cavity 
- Peritoneal dialysis  
 - Ascites“ 
 
B. Decreased pleural fluid absorption 
1. “Obstruction of pleural lymphatic drainage 
2. Disruption of Aquaporin system in the pleura 
3. Elevated systemic vascular pressure 
- Superior vena cava syndrome  
- Right ventricular failure” 
 
1. Increased Pleural Fluid Formation 
Whenever there is increased pulmonary interstitial fluid or when one of the 
terms in Starling's equation is changed, there is increased pleural fluid 
formation.  
 
a) Increased Interstitial Fluid 
“Increased interstitial fluid in the lungs is the most common cause of increased 
pleural fluid formation.” Irrespective of whether the edema is due to low-protein 
or high-protein fluid, pleural fluid accumulates whenever the amount of edema 
in the lung exceeds 5g/gram of dry lung weight. In conditions like congestive 
heart failure, parapneumonic effusions, acute respiratory distress syndrome, and 
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in those who have undergone lung transplantation, increased interstitial fluid 
appears to be the predominant mechanism for the accumulation of pleural fluid. 
 
b) Increased Hydrostatic Pressure Gradient 
According to Starling's equation, there will be an increase in the rate of 
pleural fluid formation if there is an increase in the gradient between the 
intravascular pressure and the pleural pressure.  
In conditions like right ventricular failure, left ventricular failure, 
pericardial effusion or superior vena cava syndrome, there is increase in the 
intravascular pressure. Atelectasis of the lower lobe or complete lung due to 
bronchial obstruction is the most common situation producing a decrease in the 
pleural pressure. “A decrease in the pleural pressure also occurs when the 
visceral pleura becomes coated with a collagenous peel and the lung becomes 
trapped.”  The pleural pressure can become very negative, in these instances i.e., 
it goes  below -50 cm H2O . “The decreased pleural pressures can also 
contribute to pleural fluid accumulation in diseases where the elastic recoil of 
the lung is increased.” 
 
c) Increased Capillary Permeability 
If the pleural surfaces become inflamed, the permeability of the 
capillaries may be increased. High levels of vascular endothelial growth factor 
(VEGF) increases the capillary permeability .This may be at least partially 
responsible for the accumulation of pleural fluid. It has been demonstrated that 
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mesothelial cells have VEGF receptors on their surface. The levels of VEGF are 
higher in exudative than transudative pleural effusion. 
 
d) Decreased Oncotic Pressure Gradient 
In conditions like hemothorax, increased permeability pulmonary edema                                                                                  
and with conditions in which the pleural capillary permeability is increased, the 
level of pleural fluid protein is increased. The capacity to remove pleural fluid 
by the lymphatics is approximately equal to the rate of formation of pleural 
fluid. Hypoproteinemia is a very uncommon cause of pleural effusion.  
 
e) Presence of Free Peritoneal Fluid, or Disruption of the Thoracic Duct 
or an Intrathoracic Blood Vessel : 
 The free fluid in the peritoneal cavity traverse through the holes in the 
diaphragm and it leads to pleural fluid accumulation and pleural effusion. 
Similarly, if the thoracic duct disrupts, chyle will accumulate in the pleural 
space. And if there is a disruption of a blood vessel in the thorax, blood will 
accumulate in the pleural space . 
 
2. Decreased Pleural Fluid Absorption 
a) Normal Pleural fluid absorption by lymphatics 
 Normally, “the lymphatic flow from the pleural space is approximately 
0.01 mL/kg/hour or 15 mL/day as this is the amount of pleural fluid formed. 
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However, the capacity of the lymphatics is approximately 0.20 mL/kg/hour or 
300 mL/day.” 
 
b) Obstruction of Lymphatics 
“Obstruction of the lymphatics draining the parietal pleura is the most 
common cause of decrease in pleural fluid absorption.” Lymphatic blockade is 
an important factor in the development of a malignant pleural effusion. 
 
c) Elevation of Systemic Venous Pressures 
Lymphatic flow will be reduced when there is elevation of pressure in the 
central veins.  This is because the lymphatics drain into the systemic venous 
circulation. 
“The pleural effusions developed because of (a) leakage of lymph out of 
the lymphatics that pass through the chest (these include the diaphragmatic and 
pulmonary lymphatics and thoracic duct ) ; or (b) leakage of interstitial fluid 
into the pleural space due to obstruction of lung or chest wall lymphatics .” 
 
CLINICAL MANIFESTATIONS OF PLEURAL EFFUSION  
Normally, the pleural space contains only a few millilitres of pleural fluid. If 
fluid in the pleural space is detected on a radiologic examination, it is abnormal. 
Pleural fluid accumulation is associated with many conditions. When pleural 
fluid is detected, an effort should be made to determine the etiology. 
 
18 
 
1. Symptoms 
“In a patient with pleural effusion, symptoms  mainly depends on the 
underlying process causing the effusion. Many patients have no symptoms 
referable to the effusion. When symptoms are related to the effusion, they arise 
either from inflammation of the pleura, compromise of pulmonary mechanics, 
interference with gas exchange, or rarely decreased cardiac output.” 
 
a) Pleuritic chest pain  
“Normally visceral pleura does not have pain fibres, only the parietal 
pleura contains pain fibres. In a patient with pleural effusion, pleuritic chest 
pain always indicates inflammation of the parietal pleura. Some patients with 
pleural effusions experience a dull aching chest pain rather than pleuritic chest 
pain. 
The parietal pleura is innervated mostly by the intercostal nerves. So, the 
pain associated with pleural disease is well localized and it coincides with the 
area of the pleura which is affected by disease. Since the intercostal nerves are 
also distributed to the abdomen, pleuritic  pain is referred to the abdomen .When 
the central portion of the diaphragmatic pleura is involved, there are exceptions 
to the localization of the pain. Phrenic nerve supplies this portion of the parietal 
pleura. Pain is referred to the tip of the ipsilateral shoulder if the central portion 
of the diaphragm is inflamed. Pleuritic pain felt simultaneously in the lower 
chest and ipsilateral shoulder points to diaphragmatic involvement.” 
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b) Cough  
 “A dry, non-productive cough is the  second symptom of pleural effusion. 
Although it may be related to pleural inflammation, the exact mechanism 
producing the cough is not clear. Alternately, cough reflex is stimulated by the 
pleural fluid compressing the lung, bringing the opposing bronchial walls into 
contact.” 
 
c) Dyspnea 
 “Dyspnea is the third symptom of pleural effusion. As pleural effusion 
acts as a space-occupying process in the thoracic cavity, it reduces all 
subdivisions of lung volumes leading to dyspnea. 
 This explains the small increase in pulmonary function following 
therapeutic thoracocentesis if pleural effusion is associated with parenchymal 
disease. The degree of dyspnea is frequently out of proportion to the size of the 
pleural effusion. Due to the weight of fluid on the diaphragm, the diaphragmatic 
function is compromised and this results in dyspnea .” 
 
2. Physical Examination 
a) Inspection  
 Clinical findings vary according to the pleural pressure. The ipsilateral 
hemithorax will be “larger and the usual concavity of the intercostal spaces will 
be blunted or even convex, if the pleural pressure on the side of the effusion is 
increased”. In contrast, the ipsilateral hemithorax will be “smaller and the 
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normal concavity of the intercostal spaces will be exaggerated if the pleural 
pressure on the side of the effusion is decreased.” This occurs with obstruction 
of a major bronchus or a trapped lung. In addition, the intercostal spaces retract 
with inspiratory efforts. 
An indication of therapeutic thoracocentesis is enlargement of the 
hemithorax with bulging of the intercostal spaces. It is done to relieve the 
increased pleural pressure. It is also found that the hemithoraces are equal in 
size and the intercostal spaces are normal, in many patients with pleural 
effusions. 
 
b) Palpation  
 Palpation is useful to determine the extent of the effusion. “Vocal 
fremitus is absent or attenuated in areas of the chest where pleural fluid 
separates the lung from the chest wall.” This is because the vibrations 
emanating from the lung are absorbed by the fluid. 
 To identify the upper limit of the pleural fluid, vocal fremitus is much 
more reliable than percussion. It is also useful to identify a proper site to attempt 
a thoracocentesis. Vocal fremitus is much more reliable than percussion, 
because with a thin rim of fluid, the tactile fremitus is diminished, but the 
percussion note may still be resonant.  
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Apical impulse  
 Palpation may also reveal that the apical impulse is shifted to one side or 
the other. The apical impulse may not be palpable in patients with large left 
pleural effusions. 
  
Position of trachea 
The position of the trachea in patients with pleural effusion always indicates 
the relationship between the pleural pressures in the two hemithoraces. 
 
c) Percussion  
 In a patient with pleural effusion the percussion note over the area of 
involvement is dull or flat. For identifying small amounts of pleural fluid, light 
percussion is better than heavy percussion. 
 
d) Auscultation  
 Auscultation reveals decreased or absent breath sounds. However, breath 
sounds may be accentuated and take on a bronchial characteristic, near the 
superior border of the fluid. This accentuation of breath sounds denotes a 
passively collapsed lung with a communicating bronchus. 
 
Systemic cause and clinical findings  
1. If the patient has cardiomegaly, neck vein distension, or peripheral 
edema, the effusion is probably due to congestive heart failure (CHF). 
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2. The pleural effusion is due to rheumatoid disease or systemic lupus 
erythematosus (SLE) if the patient has signs of joint disease or 
subcutaneous nodules. 
3. Metastatic disease such as breast masses should be suspected as the cause 
of pleural effusion if there is an enlarged, nontender nodular liver or the 
presence of hypertrophic osteoarthropathy.  
4. In patients with subdiaphragmatic pathology there will be abdominal 
tenderness.  
5. Tense ascites suggests cirrhosis and a hepatic hydrothorax. 
6. Lymphoma, sarcoidosis or metastatic disease should be suspected if there 
is lymphadenopathy. 
 
DIFFERENTIAL DIAGNOSIS OF PLEURAL EFFUSION  
1. Transudative pleural effusions  
A. “Congestive heart failure  
B. Cirrhosis  
C. Nephrotic syndrome  
D. Cerebrospinal fluid leaks to pleura  
E. Hypoalbuminemia 
F. Sarcoidosis 
G. Peritoneal dialysis  
H. Glomerulonephritis  
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I. Myxoedema 
J. Superior vena cava obstruction  
K. Fontan procedure  
L. Urinothorax” 
 
2. Exudative pleural effusions  
A. “Neoplastic diseases  
1. Metastatic disease  
2. Mesothelioma  
3. Pyothorax-associated lymphoma 
4. Body cavity lymphoma “ 
B. “Infectious diseases  
1. Bacterial  
2. Tuberculosis  
3. Viral  
4. Parasitic  
5. Fungal “ 
C. Pulmonary embolization  
D. “Gastrointestinal disease  
1. Pancreatic disease  
2. Subphrenic abscess  
3. Intrahepatic abscess"  
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E. Obstetric and gynecologic disease  
1. Ovarian hyperstimulation syndrome  
2. Fetal pleural effusion  
3. Endometriosis 
4. Postpartum pleural effusion  
5. Meigs' syndrome  
F. “Collagen vascular diseases  
1. Rheumatoid pleuritis 
2. Systemic lupus erythematosus” 
G. Drug-induced pleural disease  
1. Ergot drugs  
2. Amiodarone 
3. Interleukin 2  
4. Nitrofurantoin 
5. Dantrolene 
6. Methysergide 
I. Hemothorax 
J. Chylothorax” 
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GENERAL TESTS TO DIFFERENTIATE THE CAUSES OF 
EXUDATIVE PLEURAL EFFUSION: 
1. Appearance of the fluid  
“Most pleural effusions are clear, straw colored, nonviscid and 
odourless.” 
The red colour of the fluid indicates the presence of blood. To confirm 
hemothorax, a hematocrit should be done. If the hematocrit of the pleural fluid 
was more than 50 % of the peripheral blood hematocrit, then it is a hemothorax. 
When the pleural fluid is blood tinged the RBC count is 5000 to 10000 / mm3 . 
If the pleural fluid macrophages contain haemoglobin inclusions, then it 
indicates that the blood was present before thoracocentesis and the blood is not 
due to traumatic tap. 
Increased lipid content or increased cellular content both can make 
pleural fluid to appear turbid. If after centrifuge the supernatant fluid remains 
turbid then it is due to lipid content.  
Amebiasis with a hepato-pleural fistula – chocolate sauce or anchovy 
sauce pus is seen. The mixture of blood, cytolysed and normal liver tissue make 
this appearance. 
 
Malignant mesothelioma  –  High viscosity due to elevated hyaluronic acid 
.Anaerobic bacterial infection  –  Faeculent odour 
Urinothorax    –  Smell of urine 
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2.WBC count  
“Most transudates have WBC count below 1,000/mm3 and exudates have 
more than 1,000/mm3.” 
WBC count > 10,000/mm3 – parapneumonic effusions 
WBC count > 50,000/mm3 – pancreatic disease and pulmonary embolism 
Neutrophils predominate – suggests acute inflammation. It is seen in 
“pneumonia, pancreatitis, pulmonary embolism, subphrenic abscess and early 
tuberculosis”. 
Eosinophils predominate – indicates air or fluid in the pleural space. It is 
seen in patients with spontaneous pneumothorax who had undergone 
thoracotomy, introduction of air during thoracentesis into pleural space, 
traumatic hemothorax, pulmonary embolization, CABG, asbestos related 
effusion, drugs like dantrolene, bromocriptine, parasitic disease like amebiasis, 
ascariasis . 
Basophils predominate – pneumothorax, pneumonia, leukemic pleural 
involvement . 
Pleural fluid lymphocytosis - malignancy, TB, CABG, leukemia or lymphomas. 
Mesothelial cells – Tuberculosis in HIV patients. Whereas it is absent in 
complicated parapneumonic effusions, malignancy after pleurodesis. 
 
 
 
27 
 
3. Glucose levels  
“Glucose level < 60 mg / dL – malignancy, parapneumonic effusions, 
rheumatoid pleuritis, tuberculosis”. Other causes include hemothorax, lupus 
pleuritis, paragonimiasis, Churg-Strauss syndrome. 
 
4. Amylase level  
It is elevated in pancreatic disease, malignancy, esophageal rupture. In the 
latter two cases the amylase is of salivary type. 
 
5. Lactate dehydrogenase level  
 “LDH in the pleural fluid is a reliable indicator of degree of inflammation 
of the pleura. More the inflamed surfaces, higher the LDH levels. The most 
common causes of elevated LDH levels are parapneumonic effusions and 
malignancy. These two conditions mostly meet the light’s criteria on the basis 
of levels of LDH than the protein levels .The iso-enzymes elevated in these 
conditions are LDH – 4 and LDH – 5. They are thought to arise from the 
inflammatory WBCs”. 
 
 Usually LDH isoenzyme is not used routinely. This is done in conditions 
where there is a bloody pleural fluid tap in a patient who has transudative 
pleural effusion clinically. The pleural fluid protein meets the criteria for 
transudative pleural effusion but LDH levels meet the criteria for exudative 
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pleural effusion. In these conditions iso-enzyme LDH – 1 confirms that the rise 
in LDH was due to blood . 
 
6. AdenosineDeaminase  
ADA has two isoenzymes – ADA 1 and ADA 2 
ADA 1 is produced by lymphocytes, neutrophils, monocytes, macrophages 
ADA 2 is produced by macrophages and monocytes . 
“The cut off level for ADA level to diagnose tuberculous pleural effusion is 40 
to 45 U/L . The diagnosis of TB pleural effusion is more likely if the level is 
higher i.e., more than 70 U/L”.  
 
7. C–Reactive proteins more than 50 mg /L, high levels of lysozyme are also 
used to diagnose tuberculous pleuritis. 
 
8.  Lipids  
 Chylothorax –“ Accumulation of chyle in the pleural space due to 
disruption of the thoracic duct. In these situations the triglyceride levels are 
increased”. 
 Chyliform pleural effusions – This is characterised by high levels of 
lecithin globulin levels. 
 Pseudo chylous effusions – “There is increased levels of cholesterols 
crystals. Triglyceride levels more than 110 mg / dL – Chylothorax is confirmed. 
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But if the levels are less than 50 mg / dL then the patient does not have 
chylothorax”. 
 “If triglyceride level is between 50 to 110 mg / dL then a lipoprotein 
analysis should be done. Presence of chylomicrons in the lipoprotein analysis of 
pleural fluid is diagnostic of Chylothorax”. 
 
 Alkaline Phospahatase 
 “Alkaline phosphatise is a hydrolase enzyme which catalyze the removal 
of phosphate groups from nucleotides, proteins, alkaloids etc. It is mostly 
produced by liver and bone and these are the predominant forms. Other sites of 
production include kidney, intestine, placenta, pleura etc. Alkaline phosphatase 
levels are also used to differentiate transudative and exudative pleural effusion. 
A cut off value of 60 IU for Pleural fluid ALP and Pleural fluid/Serum ALP 
ratio of 0.35 is applied to classify pleural effusion into transudate or exudates.” 
 
RADIOGRAPHIC EXAMINATION OF PLEURAL EFFUSION 
Typical Arrangement of Free Pleural Fluid 
 “The distribution of free fluid in the pleural space” is governed by two 
important factors.  
 First, accumulation of the pleural fluid occurs in “the most dependent part 
of the thoracic cavity since the lung is less dense than pleural fluid”.  
 Second, the distribution of fluid within the free pleural space obeys the 
law of gravity. The lung also maintains its shape when compressed”.  
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Bearing these 2 factors in mind, it is easy to predict the distribution of excess 
pleural fluid.  
 “The fluid first gravitates to the base of the hemithorax and comes to rest 
between the inferior surface of the lung and the diaphragm, where the pleural 
sinus is the most inferior, particularly posteriorly. The fluid spills out into the 
costophrenic sinuses posteriorly, laterally and anteriorly when the fluid 
accumulation is higher. Additional fluid assumes a higher position in the thorax 
as it spreads upward in a mantle-like manner around the convexity of the lung 
and gradually tapers”.  
 “The lateral costophrenic angle is obliterated in the posteroanterior 
projection. The density of the fluid is high laterally and curves gently medially 
and downward, to terminate at the mediastinum with a smooth, meniscus-
shaped upper border. At the mediastinal border the layer of fluid is narrower 
than at the costal border”.  
 The upper surface of the pleural fluid density is semicircular in the lateral 
projection. It is high in the anterior and posterior regions. It curves smoothly 
downward to its lowest point approximately midway between the posterior 
chest wall and the sternum. 
 Frequently, in the lateral chest radiograph a middle lobe step is observed. 
The explanation for the middle lobe step is that the most dependent and the first 
affected lobe is the lower lobe, the pleural fluid starts to accumulate here. 
Therefore, it starts to float and shrink but maintains its shape. So the middle 
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lobe is unaffected and its full volume is maintained. Hence, the result is a 
middle lobe that retains its usual size and shrunken lower lobe. The fluid 
accumulation is mostly in the posterior part of the chest on radiograph. The 
height of the pleural fluid is greater laterally, based on the radiologic 
appearance. When viewed en face, this layer of fluid is of insufficient depth to 
cast a discernible shadow, so it assumes a meniscus shape. 
 
Radiologic Signs 
 The fluid first accumulates “between the inferior surface of the lower 
lobe and the diaphragm, when the patient is in the upright position”. The pleural 
fluid occupies this position if the amount of fluid is small (approximately 75 
mL) and without spilling into the costophrenic sinuses. The normal 
configuration of the diaphragm is maintained, with this small amount of fluid.  
The chest radiograph when viewed in the lateral projection, accumulation 
of more fluid obliterates the costophrenic angle as it “spills over into the 
posterior costophrenic angle”. The posterior costophrenic angle is normally 
sharp. It is obliterated by a homogeneous, shallow shadow with a meniscus-
shaped upper surface. There is also widening of the pleura that lines the 
posterior thoracic wall . 
 If the posterior part of one or both diaphragms is obscured or the 
posterior costophrenic angle is obliterated, it indicates the presence of pleural 
fluid.  
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Then we should be do further diagnostic tests. 
Moreover, “the presence of clinically significant amounts of free pleural 
fluid can be nearly excluded, if both posterior costophrenic angles are clear and 
sharp. In the postero - anterior chest radiograph, lateral costophrenic angle is 
blunted with increasing amounts of fluid. The entire outline of the diaphragm is 
lost on the affected side,” as more fluid accumulates. The fluid then extends 
upwards around the posterior, anterior and lateral thoracic walls. At the lung 
base, this fluid produces opacification which is the typical meniscus shape. 
 
Supine Position 
There are three characteristics that serve to differentiate the increased 
density due to parenchymal infiltrate from that due to a pleural fluid.  
First, in a properly exposed film, “the vascular structures of the lung will 
be readily visible through the density, if the density is caused by pleural fluid”. 
However, vascular structures are obliterated by the silhouette effect, if a similar 
density is produced by any intrapulmonary process.• 
Secondly, the density is usually completely homogenous, if it is due to 
pleural fluid. Whereas, the infiltrates are usually less homogenous, if it is caused 
by an intrapulmonary processes. Third, “the presence of air bronchograms”. 
They are present only if the “increased density is due to a parenchymal infiltrate 
and not due to a pleural fluid.” 
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Ultrasound 
In a pleural effusion , the ultrasound can be used for the following purposes. 
They are 
1. To determine the presence of pleural fluid;  
2. To identify an appropriate location for the attempted thoracocentesis, 
chest tube placement, or pleural biopsy; 
3. To identify loculated pleural effusion;  
4. To distinguish pleural thickening from  pleural fluid;  
5. To semi-quantify the amount of pleural fluid;  
6. To differentiate a lung abscess from a pyopneumothorax;  
7. to assess whether pleurodesis is present; and  
8. To evaluate the trauma patient for the presence of a pneumothorax or a 
hemothorax. 
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FIGURE 
CHEST X RAY – POSTERIOR ANTERIOR VIEW SHOWING RIGHT 
SIDED PLEURAL EFFUSION 
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FIGURE 
DIAGNOSTIC OR THERAPEUTIC THORACENTESIS 
RECOMMENDED POSITION OF THE PATIENT 
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FIGURE 
DIAGNOSTIC THORACENTESIS: THE PLEURAL SPACE IS 
ENTERED AND PLEURAL FLUID IS OBTAINED. 
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FIGURE 
CT CHEST PLAIN SHOWING PLEURAL EFFUSION 
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SEPARATION OF TRANSUDATIVE FROM EXUDATIVE EFFUSIONS 
The “accumulation of clinically detectable quantities of pleural fluid is 
distinctly abnormal”.  
Indications of diagnostic thoracocentesis: 
1. “Whenever the thickness of pleural fluid on ultrasound or the 
decubitus radiograph is greater than 10 mm” or  
2. Whenever “loculated pleural fluid is demonstrated with ultrasound”  
3. Etiology of the effusion is unknown.  
 A diagnostic thoracocentesis takes less than 10 minutes. It should not 
cause any morbidity more than a venipuncture. The information available from 
examination of the pleural fluid is invaluable in the management of the patient 
with pleural effusion. 
 
Transudative pleural effusion  
“If the systemic factors influencing the absorption or formation of pleural 
fluid are altered, transudative pleural effusion develops”. 
“The permeability of the capillaries to proteins, ALP, cholesterol is normal in 
the area where the fluid is formed”.  
 
Examples of conditions producing transudative pleural effusions : 
1. Increased pulmonary interstitial fluid and a resulting pleural effusion - left 
ventricular failure. 
2.  Movement of fluid across the diaphragm from ascites due to cirrhosis. 
39 
 
3. Decreased serum oncotic pressure with hypoproteinemia. 
 
Exudative pleural effusion  
In contrast, “when the pleural surfaces or the capillaries in the location 
where the fluid originates are altered such that fluid accumulates, an exudative 
pleural effusion develops”.  
The common causes of exudative pleural effusions are : 
1. Pleural malignancy,  
2. Parapneumonic effusions, 
3. Tuberculosis  and 
4. Pulmonary embolism. 
 
Total protein 
Earlier to separate between transudate and exudates, a pleural fluid 
protein of 3gms was used. This test misclassified about 10% of pleural 
effusions.  
Light’s criteria: 
Light demonstrated the following criteria for diagnosing exudate. 
 Exudative pleural effusions meet at least one of the following criteria  
 “Pleural fluid protein divided by serum protein greater than 0.5” 
 “Pleural fluid LDH divided by serum LDH greater than 0.6” 
 “Pleural fluid LDH greater than two thirds of the upper limit of normal 
serum LDH” 
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Other tests to differentiate exudates and transudate  
In recent years, following are the other tests for the separation of transudates 
from exudates. 
1. Pleural fluid ALP > 60 IU  
2. Pleural fluid serum ALP ratio > 0.35  
3. Pleural fluid serum albumin gradient of <1.2 
4. Pleural fluid protein gradient <3.1 
When a pleural fluid shows above findings on analysis then it indicates an 
exudative effusion.  
Light's criteria identify approximately 20% of transudative effusions as 
exudates. This “mislabeling occurs most commonly in patients with CHF”. 
When they are treated with diuretics before thoracocentesis is performed, these 
mislabeled transudates barely meet the exudative criteria. 
“The mislabeled transudate can be identified by examining the gradient between 
the serum and the pleural fluid protein levels. If this gradient is greater than 3.1 
g/dL, one can presume that the fluid is actually a transudate. An albumin 
gradient of 1.2 g/dL rather than the protein gradient of 3.1 g/dL can be used”. 
However, the protein gradient is equally effective as the albumin gradient. Also 
the pleural fluid bilirubin and cholesterol can be used to correctly identify the 
transudates and exudates. 
“If the pleural fluid ALP is more than 60IU and pleural fluid to serum 
ALP ratio is more than 0.45, then it is an exudate”. 
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Approach to diagnose a transudative or exudative pleural effusion  
First assess the fluid for Light's criteria. The fluid is more likely an 
exudate if there is “higher the value for the protein ratio, the LDH ratio, and the 
absolute value of the LDH. If the fluid meets the criteria for a transudative 
effusion, it is a transudate”.  
“If the fluid meets the criteria for an exudative effusion by only a small 
margin and the clinical picture is compatible with a transudative effusion, 
measure the protein gradient between the serum and pleural fluid. If this value is 
greater than 3.1 g/dL, then the fluid can be relabelled a transudate”. 
And if the “pleural fluid ALP is more than 60IU and pleural fluid to serum ALP 
ratio is more than 0.45,” then it is an exudate. 
 
Other Characteristics of Transudates 
Most transudates are clear, straw coloured, non - viscid, and odourless. 
The discovery of blood-tinged pleural fluid does not mean that the fluid is not a 
transudate. To give the pleural fluid a pinkish tinge, pleural fluid red blood cell 
(RBC) count should be more than 10,000/mm3. Approximately 15% have RBC 
counts above this level. RBCs contain a large amount of LDH. So elevated   
LDH level in a blood-tinged or bloody transudative pleural effusion would meet 
the criteria for an exudative pleural effusion. 
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White blood cell (WBC) count  
White blood cell (WBC) count in the pleural fluid of most transudates is 
less than 1,000/mm3, but approximately 20% have WBC counts that exceed 
1,000/mm3. WBC counts in pleural fluid above 10,000/mm3 are rare in 
transudative pleural effusions. The differential WBC count may be dominated 
by polymorphonuclear leukocytes, small lymphocytes, or other mononuclear 
cells in transudative pleural effusions.  
In a series of 51 transudative effusions, 7 (13%) had more than 50% 
polymorphonuclear leukocytes, whereas 17 (34%) had predominantly small 
lymphocytes, 23 (47%) had predominantly other mononuclear cells, and 4(6%) 
had no single predominant cell type . 
“The glucose level in pleural fluid is similar to the serum glucose level, 
but the level of pleural fluid amylase is low. Because of active transport of 
bicarbonate from the blood into the pleural space, there is always higher pleural 
fluid pH in patients with transudative pleural effusions than the pH in 
simultaneously obtained blood”. 
 
Diagnostic Thoracocentesis  
If the decubitus film demonstrates presence of free pleural fluid, then one 
should consider performing a diagnostic thoracocentesis with the aid of 
ultrasound or with a CT scan. The thickness of the fluid is important in 
performing the diagnostic thoracentesis. It is difficult to perform a diagnostic 
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thoracocentesis if “the thickness of the fluid on the decubitus radiograph, 
ultrasound, or the CT scan is less than 10 mm”. However, “if the thickness of 
the fluid is greater than 10 mm, we have to consider performing a diagnostic 
thoracocentesis”. 
There is no need to perform diagnostic thoracentesis if the patient has 
congestive heart failure. But in a patient with congestive heart failure if any of 
the following three conditions are met: “ (a) the patient is febrile (b) the 
effusions are not bilateral and comparably sizd (c) the patient has pleuritic chest 
pain”, a  diagnostic thoracocentessis is done later, “if the pleural effusions do 
not rapidly disappear. Otherwise, treatment of the congestive heart failure is 
initiated”.  
To sum up, the main aim of performing a diagnostic thoracentesis is to 
determine whether the patient has an exudative or a transudative pleural 
effusion. 
 
TRANSUDATIVE PLEURAL EFFUSION 
Alternation in the “systemic factors influencing the formation and absorption of 
the pleural fluids leads to accumulation of the pleural fluid and formation of 
transudative pleural effusions”. 
The major causes are: 
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1. Congestive Heart Failure: 
The most common cause of pleural effusion is probably the congestive 
heart failure (CHF). The incidence of pleural effusions in patients with CHF is 
high. 
 
Pathophysiology  
According to Starling's equation, “the increased pressures result in a 
decreased removal of fluid through the visceral pleura and an increased entry of 
fluid into the pleural space from the parietal pleura”. In patients with CHF, 
according to  current theories on pleural fluid formation and reabsorption, there 
is “a  different entry pathway and a different exit pathway for pleural fluid”. 
 “It is believed that almost all fluid exits the pleural space through the 
lymphatics in the parietal pleura rather than by passively diffusing across the 
visceral pleura. In patients with CHF, pleural effusion occurs when the rate of 
entry of fluid into the pleural space exceeds the capability of the lymphatics in 
the parietal pleura to remove the fluid”. 
 
Clinical Manifestations 
“In patients with pleural effusions due to CHF they are usually associated 
with other manifestations of that disease. The patient has a history of increasing 
dyspnea on exertion, orthopnea or paroxysmal nocturnal dyspnea, increasing 
peripheral edema. The dyspnea is frequently out of proportion to the size of the 
effusion”.  
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Physical examination 
Physical examination usually reveals “signs of the pleural effusions as 
well as signs of both left-sided heart failure with an S3 ventricular gallop and 
rales and right-sided heart failure with peripheral edema and distended neck 
veins”. 
 
Investigations 
The chest radiograph almost always reveals usually bilateral pleural 
effusion and cardiomegaly. “Congestive heart failure is the most common cause 
of bilateral pleural effusion. But only 88% of the patients studied had bilateral 
pleural effusion, if cardiomegaly is not present”. 
“The mean volume of pleural fluid in the right pleural space (1,084 mL) 
when compared to the mean volume of pleural fluid in the left pleural space 
(913 mL) was only slightly greater. Also mediastinal lymphadenopathy is 
common in patients with pleural effusions that are secondary to CHF”.  
 
Diagnosis 
If the patient has bilateral pleural effusions and cardiomegaly, not febrile 
and no history of pleuritic chest pain, we have to initiate treatment of CHF. 
Then we have to observe the patient and determine whether the pleural fluid is 
reabsorbed. A diagnostic thoracocentesis should then be done if the effusions do 
not disappear within a few days.  
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One problem with this approach is that “the characteristics of the pleural fluid 
may change from those of a transudate to those of an exudate, since the patients 
are on diuretics”.  
 
Serum pleural fluid albumin or protein gradient 
“The serum to pleural fluid protein gradient should be examined if the 
pleural fluid meets exudative criteria but the effusion is thought to be due to 
CHF. If this gradient is greater than 3.1 g/dL, additional diagnostic studies are 
not indicated because the pleural effusion is probably due to the CHF. 
Currently, as the protein gradient is already available when Light's criteria are 
measured, the protein gradient of 3.1 g/dL is preferred to the albumin gradient.” 
 
Pro-brain natriuretic peptide: 
“The measurement of the serum or pleural fluid pro-brain natriuretic 
peptide (pro-BNP) is another test that should be considered for establishing the 
diagnosis of CHF. The level of NT pro-brain natriuretic peptide (NT pro-BNP) 
considered diagnostic of CHF is 1500pg/mL”. 
 
Treatment 
In a patient with pleural effusion secondary to heart failure the preferred 
treatment is to treat the heart failure with the following drugs: 
- digitalis 
- diuretics – to reduce preload and  
- dilators - to reduce afterload .  
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The pleural effusion disappears if we manage heart failure successfully. 
In most patients with heart failure, the pleural effusion is effectively managed 
only with above management. 
Occasionally, the patients tend to be very dyspneic, if large pleural 
effusion is present. Such persons may get rapid relief from the dyspnea if about 
0.5L to 1.0L of pleural fluid is removed. Sometimes therapeutic thoracocentesis 
is indicated to get symptomatic relief in patients with heart failure and large 
pleural effusions that are refractory to treatment. So consider interventions to 
control the pleural effusions in such patients. 
 
2. Hepatic Hydrothorax 
One of the complications of hepatic cirrhosis is pleural effusion. But only 
when ascitic fluid is present, pleural effusion occurs which is called as hepatic 
hydrothorax. 
 
Pathophysiology 
It is evident from the foregoing studies that “ascitic fluid is the origin of 
pleural fluid in these patients”.  
“The fluid in the peritoneal cavity passes directly through the defects in 
the diaphragm to the pleural space”. The diaphragm may be stretched in patients 
with tense ascites, causing microscopic defects. This is because of the 
“Increased intraabdominal pressure”.  There is always a “one-way transfer of 
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fluid from the peritoneal to the pleural cavity in patients with ascites”. This is 
because of increased hydrostatic pressure in the ascitic fluid. 
In some patients, “the lymphatics play an important role in the production 
of the pleural effusion. The mechanism behind this is the transfer of ascitic fluid 
across the diaphragm by the lymphatic vessels”. 
Therefore, the dominant mechanism of hepatic hydrothorax is the direct 
movement of fluid across the diaphragm.  
 
Clinical Manifestations 
The clinical pictures of cirrhosis and ascites dominate in patients with 
pleural effusion secondary to cirrhosis. At times, in association with large 
pleural effusions, these patients develop acute dyspnea. “Although the pleural 
effusions may be small to moderate in size, they are frequently large and occupy 
the entire hemithorax. The diaphragmatic defect permits fluid to flow into the 
pleural cavity from the peritoneal cavity until the pleural pressure approaches 
the peritoneal pressure and this results in development of  large pleural 
effusion”. 
 
Diagnosis 
It is usually easy to diagnose the pleural effusion that is secondary to 
cirrhosis with ascites. We should perform both a paracentesis and a 
thoracocentesis. This is to confirm that the ascites and pleural fluid are 
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compatible with the diagnosis. Also to ascertain that they do not have high 
polymorphonuclear cell counts.  
The pleural fluid is occasionally blood tinged or is frankly bloody. But 
such findings have no significance due to the poor coagulation status of the 
patient. The differential cell count is dominated by polymorphonuclear 
leukocytes, small lymphocytes, or other mononuclear cells.  
To rule out pancreatic ascites amylase levels should be determined. Also 
a cytologic examination should be performed to rule out malignant disease. This 
should be done in both pleural fluid and ascitic fluid. 
 
Treatment 
“Since the hydrothorax is an extension of the peritoneal fluid in patients 
with cirrhosis and ascites, the management of pleural effusion should always be 
directed towards the treatment of ascites”.  
The patient should be put on a “low-salt diet and moderate fluid 
restriction. Then diuretics should be administered. The combination of 
furosemide and spironolactone is the best diuretic therapy. The initial starting 
dose is 40 mg of furosemide and 100 mg of spironolactone and they can be 
titrated upto a maximum dose of 160 mg of furosemide and 400 mg of 
spironolactone”. 
 
3. Nephrotic Syndrome 
 Nephrotic syndrome is common in patients with pleural effusion. 
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Mechanism 
 “The combination of increased hydrostatic pressure and decreased plasma 
oncotic pressure is the mechanism responsible for the transudative pleural 
effusion in patients associated with the nephrotic syndrome”.  
 
Diagnosis 
In the typical clinical situation, “it is not difficult to diagnose pleural 
effusion secondary to nephrotic syndrome. But to confirm that the pleural fluid 
is indeed a transudate, a diagnostic thoracocentesis should be performed”.  
“In patients with the pleural effusion and nephrotic syndrome, the 
possibility of pulmonary embolism should always be considered. In all patients 
with the pleural effusion and nephritic syndrome , one should always obtain a 
lung scan or a CT angiogram”. It is important that evidence of deep venous 
thrombosis should be sought with venogram, pulmonary arteriogram or 
impedance plethysmogram, if the lung scan or spiral CT scan is equivocal.  
Treatment 
The main aim of treatment is to decrease the protein loss in the urine of 
patients with pleural effusion and associated with nephrotic syndrome. This is 
done to decrease the increased extracellular volume and to increase the plasma 
protein.  
This is best accomplished by administering  
- diuretics in conjunction with a low-sodium diet,  
- angiotensin-converting enzyme inhibitors.  
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As serial therapeutic thoracocentesis only deplete the protein stores, it 
should not be performed. We should consider “pleurodesis with a sclerosing 
agent in selected patients who are symptomatic”. 
 
EXUDATIVE PLEURAL EFFUSION  
MOST COMMON CAUSES ARE 
1. Parapneumonic pleural effusion 
2. Pleural effusion related to metastatic malignancies 
3. Tuberculous pleural effusion 
 
1. METASTAIC MALIGNANCIES AND PLEURAL EFFUSION: 
 “The exudative pleural effusion secondary to malignant disease involving 
the pleura is the second leading cause of exudative pleural effusion. 
Parapneumonic effusion ranks first in this category”. 
Common carcinomas associated with malignant pleural effusions are: 
1. “Lung carcinoma 
2.  Breast carcinoma 
3.  Lymphoma” 
4.  Ovarian carcinoma 
5.  Sarcoma 
Rarely carcinoma of uterus, cervix, stomach , colon , pancreas , bladder  
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MECHANISM 
1. Direct mechanism: 
a) Increased permeability due to pleural metastasis 
b) Obstruction of the pleural lymphatic vessels caused by pleural metastasis 
c) Decreased pleural lymphatic drainage and mediastinal node involvement 
d) Chylothorax – thoracic duct interruption 
e) Decreased pleual pressure – bronchial obstruction 
f) Due to involvement of pericardium 
2. Indirect mechanism: 
a) Pulmonary embolism 
b) Postobstructive pneumonitis  
c) Hypoproteinemia 
d) Postradiation therapy 
 
CLINICAL MANIFESTATIONS 
The most common symptom in patients with malignant pleural effusion is 
dyspnea. Also the symptoms due to the underlying disease will predominate. 
The symptoms due to underlying malignancy are weight loss, malaise, anorexia. 
The other manifestations are  chest pain, hemoptysis, cough in patients with 
lung malignancy, breast mass in carcinoma breast, swelling in neck, axilla 
inguinal regions with mass in the abdomen in case of lymphomas . 
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Chest radiograph: Besides the pleural effusion, pulmonary abnormalities are 
demonstrated in patients with pleural effusion secondary to carcinomas. Also 
there is involvement of mediastinal lymphadenopathy . 
The pulmonary abnormalities are: 
a) pleural nodularity ,  
b) pleural rind ,  
c) mediastinal pleura involvement ,  
d) pleural thickening > 1 cm  
 
Pleural fluid analysis 
 “Grossly bloody with RBC count > 100,000/mm3. 
 WBC count between 1,000 to 10,000 / mm3 with lymphocytes 45 % other 
mononuclear cells > 40% , polymorphonuclear cells  15 % . 
 Reduced pleural fluid glucose level less than 60 mg/ dl. 
 Pleural fluid pH below 7.3 
 Cytology: It is used to classify the histological subtype like 
adenocarcinoma but not the primary site of tumour. 
 Immunohistochemical tests: Carcinoembryonic antigen is detected in 
metastatic adenocarcinoma and also stains MOC 3,1,B72.3,Ber – EP4 and 
BG – 8. Malignant mesothelial cells stain positive for cytokeratin and 
calretin. 
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 Tumormarkers: Carcinoembyronic antigen (CEA), carbohydrate 
antigen (CA) 15 – 3, 19 – 9, 549 and 72.Neuron specific enolase ,SCC 
antigen , SSEA – sialyl state specific mouse embryonic antigen, 
cytokeratin 19 fragments”  . 
 
Non-invasive test 
This includes measurement of oncogenes, lectin binding, FISH,  flow 
cytometry, proteomics, chromosomal analysis and hyaluronic acid. 
But the only test that is advised is flow cytometry. This is done when a 
lymphoma is suspected. The diagnosis of lymphoma is done by showing the 
clonality of lymphocytes in pleural fluid. 
Pleural biopsy – CT guided or via thoracoscopy 
 
TREATMENT: 
In the management of pleural effusion due to metastatic disease the 
important thing is to identify the site of primary. This is to decide whether the 
primary tumor responds to systemic chemotherapy or not. Because some 
tumours like breast carcinoma, lymphoma, small cell carcinoma respond to 
systemic chemotherapy very well. 
Also intrapleural chemotherapy with cisplatin, staphylococcus aureus 
super antigen (SSAg), rituximab, interferon – gamma, tumour necrosis factor, 
interleukin IL -2 has been tried with varying results. 
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In patients with malignant pleural effusion and a chylothorax, malignancy 
usually involves the thoracic duct. So in these patients it is good to administer 
radiotherapy to the mediastinum. 
We have to consider removal of the pleural fluid if the tumor is not 
responding to chemotherapy or fails to respond to treatment. This is done 
mainly to relieve the dyspnea. 
 
The procedures available for the chemotherapy resistant pleural effusion are: 
1. Indwelling pleural catheter  ( pleur X ) 
2. Pleurodesis 
3. Intercostal drainage 
4. Pleuroperitoneal shunt  
5. Repeated thoracentesis 
6. Pleurectomy 
 
2. TUBERCULOUS PLEURAL EFFUSION  
 The development of pleural effusion in a patient with absence of 
radiologically apparent TB indicates that it would be a sequelae to the primary 
infection that occurred   6 to 12 weeks before or it may be due to reactivation of  
TB . 
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Pathogenesis 
In tuberculous patients there are subpleural caseous foci. Tuberculous 
pleural effusion occurs due to” rupture of the subpleural caseous focus in the 
lung to the pleural space”. 
“In the development of tuberculous pleural effusion the delayed 
hypersensitivity plays a major role”. There is clonal expansion of lymphocytes 
sensitised to the tuberculous protein. “Initially the macrophages predominate in 
the pleural fluid from day 2 to day 6 and then the lymphocytes predominate in 
the pleural fluid”. 
“It is clear that the delated hypersensitivity increases the permeability of 
pleural capillaries to protein. There is higher rate of pleural fluid formation due 
to the increased levels of pleural fluid protein. Also there is increased level of 
VEGF, which also increases the permeability. This leads to the accumulation of 
pleural fluid and development of pleural effusion”. 
Also there is decrease in the clearance of proteins in the pleural space. 
This is because of the impedence to the clearance of proteins by the lymphatics 
as a result of delayed hypersensitivity reactions. 
 
Clinical manifestation: 
“Patients with pleural TB have symptoms such as fever, dry cough, 
pleuritic chest pain and dyspnea.  
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Physical findings are those of pleural effusion such as dullness on percussion 
and absence of breath sounds. 
In HIV individuals there will be longer duration of illness. The incidence 
of chest pain is low, but night sweats, fatigue, diarrhoea, hepatomegaly, 
lymphadenopathy , splenomegaly  are more common.  
They have associated parenchymal lesions, smear for acid fast bacilli 
positive and also culture positive for AFB”. 
 
DIAGNOSIS 
Tuberculin skin testing: “Tuberculin skin testing is almost always 
positive if performed after 8 weeks of development of symptoms. So a negative 
skin testing after 8 weeks of development of symptoms can be used to rule out 
TB. However in malnourished individuals or HIV patients the test remains 
negative”. 
 
Pleural fluid analysis 
1. Pleural fluid protein elevated and usually above 5 g/dL 
2. Differential WBC count has more than 50% lymphocytes. If there are 
eosinophils, it suggests previous thoracentesis or associated 
pneumothorax . 
3. Mesothelial cells not more than 5 % 
4. Adenosine deaminase levels more than 70 U/L 
5. Interferon gamma levels more than 3.7IU/ml 
58 
 
6. Low pleural fluid pH and CRP levels more than 30 mg/dl 
7. Pleual biopsy – demonstration of parietal pleura granuloma, AFB, 
caseous necrosis. 
8. Pleual fluid AFB staining and culture for mycobacteria 
 
3. Parapneumonic effusion: 
“When any pleural effusion is associated with bacterial pneumonia, lung 
abscess or bronchiectasis , it is called as parapneumonic effusion”. 
“An empyema is defined as pus in the pleural space. Many complicated 
parapneumonic effusions are usually in the form of empyema.” 
According to Weese et al. empyema is charecterised by specific gravity 
greater than 1.018 , protein more than 2.5 g/dL , WBC count  more than 500 
cells/ mm3 But according to Vianna empyema is defined as pleural fluid protein 
more than 3.0 g/dL , WBC greater than 15000 / mm3 or positive bacterial 
cultures. 
 
Pathogenesis 
1. Exudative stage 
 “This stage is characterised by rapid accumulation of sterile pleural 
effusion. Due to increased capillary permeability, the fluid originates from the 
interstitial spaces of lung and also from the visceral pleural capillaries. There is 
low WBC count, low LDH level and a normal glucose level in the pleural fluid 
at this stage. This stage resolves if appropriate antibiotics are instituted”. 
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2. Fibropurulent stage 
 The pleural space is invaded by the bacteria if antibiotics are not intiated.  
In this stage there is accumulation of large amounts of pleural fluid which is 
rich in bacteria, polymorphonuclear leucocytes and cellular debris. A 
continuous sheet of fibrin covers the visceral and parietal pleura. This leads to 
the loculation and prevents the spread of pus. But this makes the insertion of 
chest tube difficult. In this stage there is higher pleural fluid LDH and lower 
pleural fluid glucose and pH 
 
3. Organisation stage 
This stage is characterised by pleural peel. The fibroblasts grow in to the 
exudates and an inelastic membrane is produced. The lung is encased by this 
inelastic pleural peel and makes it functionless. The exudate is thick at this stage 
and it may spontaneously drain through the chest wall called as empyema 
necessitans or into the lung producing a broncho-pleural fistula. 
The most common organisms are Staphylococcal aureus, Escherichia coli 
and anaerobic Bacterioids . 
 
Clinical features  
 Fever, cough with expectoration, chest pain are the major symptoms. 
Fever may be absent in immune-compromised patients. If the fever is present 
for more than 48 hours after the institution of antibiotics it is called as 
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parapneumonic effusion. It is important to elicit history of alcoholism, seizures 
or an episode of unconsciousness as it leads to aspiration. 
 
Light’s classification for parapneumonic effusions and empyema: 
1. “Non-significant pleural effusion 
2. Typical parapneumonic pleural effusion 
3. Borderline complicated pleural effusion 
4. Simple complicated pleural effusion 
5. Complex complicated pleural effusion 
6. Simple empyema 
7. Complex empyema” 
 
Diagnosis 
1. During thoracocentesis, there is frank pus. 
2. The pleural fluid will be positive for  Gram stain & culture.  
3. Pleural fluid glucose less than 40 mg / dL , pH < 7.0 , LDH > 3 times the 
upper limit. 
The above findings along with loculations constitute bad prognostic factors 
for both empyema and parapneumonic effusions. 
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Management 
Antibiotics 
Community acquired pneumonia: 
- Fluroquinolones such as levofloxacin, moxifloxacin, gatifloxacin or a 
macrolide such as azithromycin, clarithromycin plus beta lactams such 
as cefotaxime, ceftriaxone, ampicillin – sulfbactam . 
- If pseudomonas is suspected anti pseudomonas antibiotics like 
meropenem, imipenem, piperacillin-tazobactam or cefepime is used. 
 
Anaerobes – metronidazole or clindamycin. 
MRSA – vancomycin 
 
Management for pleural effusions 
1. Therapeutic thoracocentesis 
2. Tube thoracostomy 
3.Intrapleural fibrinolytics like streptokinase, streptodornase, tissue 
plasminogen activator 
4. Video assisted thoracoscopy with lysis of adhesions and / or decortication 
5. Decortication 
6. Open drainage 
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MATERIALS AND METHODS 
STUDY POPULATION 
This study is to be conducted among 60 patients with pleural Effusion , 
attending the Department of  Medicine & Department of  Thoracic Medicine in 
Govt. Rajaji Hospital, Madurai. 
 
Inclusion criteria 
 “In Patients with clinical and radiological evidence of pleural effusion 
irrespective of etiology,  both sex 
 Age > 12 years” 
 
Exclusion criteria 
 “Age less than 12 years 
 Prgnancy 
 Jaundice 
 Bone lesions” 
 
ANTICIPATED OUTCOME: 
“Pleural fluid alkaline phosphatase and ratio to serum levels is superior or 
supportive to Light’s criteria in differentiating transudates and exudates”. 
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DATA COLLECTION 
 “A Brief history with clinical examination will be done. 
 Detailed Clinical Examination , 
 Pleural fluid alkaline phosphatase, Serum alkaline phosphatase ,  
Pleural fluid total protein, Serum total protein  ,  Pleural & Serum 
LDH  are estimated.” 
 
LABORATORY INVESTIGATIONS 
1. “Pleural fluid alkaline phosphatase & Serum alkaline phosphatase “ 
2. “Pleural fluid total protein & Serum Protein”  
3. “Pleural fluid LDH & Serum LDH” 
 
STUDY PROTOCOL 
 “Patients with clinical and radiological evidence of pleural effusion 
are to be included in the study. 
 Then  they are classified in to exudates and transudates on the basis of 
the clinical , radiological and biochemical evaluation . 
 In all the patients following investigation are done to classify them as 
exudates and transudates 
 Pleural fluid alkaline phosphatase & Serum alkaline phosphatase, 
Pleural fluid total protein are estimated and the patients are classified 
in to exudates and transudates. 
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 Then the patients are classified in to exudates and transudates on the 
basis of Light’s criteria” 
3. “Now the classification of exudates and transudates done on the basis of 
Pleural fluid alkaline phosphatase & Serum alkaline phosphatase is 
compared with results of the classification of exudates and transudates 
done on the basis of  Light’s criteria.” 
 “Sensitivity, specificity , Positive predictive value , negative 
predictive value ,  diagnostic accuracy of each tests are calculated”. 
 
DESIGN OF STUDY 
Prospective analytical study 
 
PERIOD OF STUDY 
MAY 2016 TO NOVEMBER 2016 
 
COLLABORATING DEPARTMENTS: 
 Department of Medicine, Thoracic medicine , Biohemistry 
 
CONSENT: Individual written and informed consent. 
 
ANALYSIS:  Statistical analysis 
 
CONFLICT OF INTEREST: Nil 
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Method of study 
This study was conducted in Govt. Rajaji Hospital, Madurai which is 
affiliated to Madurai Medical College. This study subjects were selected from 
the patients admitted in Department of Medicine and Department of Medicine , 
Govt. Rajaji Hospital. 
The study was conducted in 60 patients; the patients had pleural effusion 
with clinical background of congestive cardiac failure, chronic liver disease , 
chronic kidney disease ,tuberculosis , parapneumonic effusions , malignancy. 
The patients are examined clinically with the following parameters and only 60 
patients are taken for study. 
 
Clinical criteria to classify patients as exudates and transudates  
“If the patient had oedema legs, ascites, cardiac enlargement, radiological 
evidence of congested lungs and responded to treatment for congestive cardiac 
failure , then the diagnosis of congestive cardiac failure was made”. 
When there were raised serum urea and creatinine levels along with signs 
and symptoms indicating volume overload, chronic kidney disease was 
diagnosed. 
If the patient had features of liver cell failure,ascites, spleenomegaly and 
evidence of volume overload status , chronic liver disease was diagnosed. 
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 The diagnosis of tuberculosis was made if there is cough , fever with 
evening rise of temperature, loss of weight and appetite ,sputum showing  AFB, 
ADA in pleural fluid ,chest x ray showing pleural effusion ,response to ATT. 
The diagnosis of parapneumonic effusion was made if there is cough with 
expectoration, fever with chills & rigors, chest x-ray showing pleural effusion, 
bacteria in pleural fluid/sputum. 
 The diagnosis of malignant pleural effusion was made if there is Pleural 
fluid cytology, Pleural biopsy, demonstration of primary sites. 
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Study protocol  
 “Patients with clinical and radiological evidence of pleural effusion 
are to be included in the study” 
 Then  they are classified in to exudates and transudates on the basis of 
the clinical , radiological and biochemical evaluation  . 
 In all the patients following investigation are done to classify them as 
exudates and transudates 
 Pleural fluid alkaline phosphatase & Serum alkaline phosphatase ,  
Pleural fluid total protein are estimated and the patients are classified 
in to exudates and transudates. 
 “Then the patients are classified in to exudates and transudates on the 
basis of Light’s criteria”. 
 “Now the classification of exudates and transudates done on the basis 
of Total Pleural fluid alkaline phosphatase and its ratio to serum , 
Pleural fluid Total protein  are compared with results of the 
classification of exudates and transudates done on the basis of  Light’s 
criteria”. 
 “Sensitivity , specificity , Positive predictive value , negative 
predictive value ,  diagnostic accuracy  of each tests are calculated” . 
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RESULTS AND INTERPRETATION 
   
Age group Frequency Percent 
<25 years 2 3.33 
26 – 40 years 8 13.33 
41 – 55 years 18 30.00 
56– 70 years 31 51.67 
>70 years 1 1.67 
Total 60 100.00 
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Gender Frequency Percent 
Female 25 41.67 
Male 35 58.33 
Total 60 100.00 
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Clinical classification Frequency Percent 
Exudates 33 55.00 
Transudates 27 45.00 
Total 60 100.00 
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Etiology Frequency Percent 
Tuberculosis 18 30.00 
Malignant pleural 
effusions 
10 16.67 
Parapneumonic effusions 5 8.33 
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Etiology Frequency Percent 
CCF 10 16.67 
CKD 8 13.33 
Hepatic hydrothrorax 9 15.00 
Total 60 100.00 
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Descriptive          
statistics 
Pleural 
Fluid 
Protein 
(gm/dl) 
PLEURAL 
FLUID ALKAL 
INE  
PHOSPHATASE 
mg/dl 
  
Mean 3.04 0.43 0.61 49.98 
Standard Deviation 0.53 0.121 0.14 19.69 
Minimum 2.1 0.2 0.32 16 
Maximum 4.4 0.61 0.9 80 
 
Criteria 
Correctly classified as 
transudate N (%) 
Wrongly classified as 
exudate N (%) 
Light ‘s criteria 24 (88.8%) 3 (11.2%) 
PLEURAL 
FLUID ALKAL 
INE  
PHOSPHATASE 
25 (92.5%) 2 (7.5%) 
Pleural fluid / Sr 
Alkaline 
Phosphatase 
Ratio 
24 (88.8%) 3 (11.2%) 
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Criteria 
Correctly classified 
as Exudate N (%) 
Wrongly classified as 
Transudate N (%) 
Light ‘s criteria 27 6 
PLEURAL FLUID ALKAL 
INE  PHOSPHATASE 
29 4 
Pleural fluid / Sr Alkaline 
Phosphatase Ratio 
31 2 
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75 
 
Age   and sex distribution of the population in our study is as follows  
51% of the study subjects were in the age group of 56-70yrs, 30% were in 
the age group of 41-55yrs, 16.66% were less than 40 years and 1.67% above 70 
years. 
Majority of the study subjects were males 58% while remaining 42% 
were females. 
 
Exudates and transudates distribution in our study is as follows: 
In our study about 55% of the study subjects were exudates while 45% 
were transudates . 
Among the exudates, about 30 % of study groups have tuberculosis , 17 
% have malignancy and 8 % have parapneumonic effusions. 
Among the transudates, about 17% were CCF, 13% were CKD and the 
remaining 15% were Hepatic hydrothorax. 
“Pleural fluid Alkaline phosphatase, Serum Alkaline phosphatase, Pleural 
fluid total protein , Serum total protein , Pleural fluid LDH , Serum LDH  are 
estimated”. 
 
Pleural fluid Total protein   
Any serous membrane inflammation often leads to increased capillary 
permeability and this enables the diffusion of protein. 
The permeability of pleura is increased due to “serum leakage” and this 
leads to the accumulation of ALP in exudative pleural effusion . 
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In our study to diagnose exudates the following parameters are used : 
A pleural fluid alkaline phosphatase of more than 60 IU 
“A pleural fluid alkaline phosphatase to serum alkaline phosphatase ratio of 
more than 0.45” 
 
RESULTS 
 
 “By applying Light’s criteria in patients with exudative pleural effusion 
classified clinically, 81.8% % of the cases were correctly diagnosed as 
exudative  pleural effusion. 
 By applying Pleural fluid Alkaline phosphatase in patients with exudative 
pleural effusion classified clinically, 87.8% of the cases were correctly 
diagnosed as exudative pleural effusion. 
  According to Pleural fluid/Serum Alkaline phosphatase ratio, patients 
with exudative pleural effusion classified clinically, 93.9% of the cases were 
correctly diagnosed as exudative pleural effusion. 
In our study by applying the Lights criteria, about 18.28 % of  exudative 
pleural effusion was misclassified  as  transudative, and by applying Pleural 
fluid alkaline phosphatase and Pleural fluid  , the misclassification was  12.2% 
and 25 % respectively . Whereas  by Pleural fluid  / Serum alkaline phosphatase 
ratio , the misclassification was only 3.58 %.  
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By applying Light’s criteria in patients with transudative pleural effusion 
classified clinically , 90.90 % of the cases were correctly diagnosed as 
transudative pleural effusion. 
By applying  Pleural fluid alkaline phosphatase in patients with 
transudative pleural effusion classified clinically , 86.36 % of the cases were 
correctly diagnosed as transudative  pleural effusion. 
  According to Pleural fluid  / Serum alkaline phosphatase ratio , in patients 
with transudative pleural effusion classified clinically, 90.90 % of the cases 
were correctly diagnosed as transudative pleural effusion. 
Among the  parameters used most specific test to classify an exudative 
pleural effusion from a transudative pleural effusion is pleural fluid total protein 
which is  95.45 %  and most sensitive test is pleural fluid / serum alkaline 
phosphatase ratio which is 93.90 %. The positive predictive value, negative 
predictive value and diagnostic accuracy to classify an exudative pleural 
effusion from a transudative pleural effusion is higher for pleural fluid total 
protein  which is 96.29 % , 95.23 % , 94 % respectively . 
The sensitivity , specificity , positive predictive value, negative predictive 
value and diagnostic accuracy of Light’s criteria  are 85.71 % , 90.90 % , 92.30 
% , 83.33 % , 88 % respectively .” 
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DISCUSSION 
 “One of the most common disease entity encountered by physicians 
worldwide is pleural effusion . In a situation where undiagnosed pleural 
effusion has come upon, the first and foremost thing to be resolved is whether 
the fluid is a transudate or exudate. The most frequently used Light's criteria, 
though still considered as a gold standard, often misclassify a transudate as an 
exudates. The present study was undertaken to evaluate the efficacy of pleural 
fluid alkaline phosphatase and its ratio to serum levels, and pleural fluid total 
protein in distinguishing pleural fluid transudates and exudates and its 
correlation with Light’s criteria“.  
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SUMMARY OF PRIOR PUBLICATIONS 
 
1) “The following persons namely K.B. Gupta, Veena Ghalaut, Prem 
Parkash Gupta, Puneet Arora,  S. Tandon of Pt. B.D.Sharma Postgraduate 
Institute of Medical Sciences, Rohtak have conducted the study to evaluate 
the efficacy of pleural fluid alkaline phosphatase and its ratio to serum levels to 
classify pleural fluids as exudates.”  
 
Methods and results 
“A total of 80 patients were divided into transudates and exudates on the 
basis of extensive clinical, radiological and biochemical evaluation. Up to 89% 
transudates misclassified by Light’s criteria were correctly classified by pleural 
fluid alkaline phosphatase (P ALP) and pleural fluid/serum alkaline phosphatase 
ratio (P/S ALP) evaluation. Similarly 92% exudates misclassified by Light’s 
criteria were correctly classified by pleural fluid alkaline phosphatase (P ALP) 
and pleural fluid/serum alkaline phosphatase ratio (P/S ALP) evaluation.” 
 
2) “Ashish Anantrao Jadhav, Jayashree Suhas Bardapurkar1, Anuradha Jain 
of Department of Biochemistry, People’s College of Medical Sciences and 
Research Centre,Bhopal, MP, 1Government Medical College, Aurangabad, 
Maharashtra, India have done a study on 60 patients to test the signficance 
of pleural fluid alkaline phosphatase and pleural fluid/serum alkaline 
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phosphatase ratio in differentiating exudative from transudative pleural 
effusion”.  
 
Results 
“The mean pleural alkaline phosphatase and pleural fluid/serum alkaline 
phosphatase ratio was significantly higher in exudates compared to transudates. 
(P < 0.0001). Sensitivity and specificity values were 90% and 80% for a cut-off 
value of 71 IU/L for pleural alkaline phosphatase activity; and were 90% and 
86.66% for a cut-off value of 0.51 for pleural fluid/serum alkaline phosphatase 
ratio.”  
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DEFINITIONS 
Diagnostic accuracy : “This is the probability that a randomly selected subject 
is correctly diagnosed by the test” . 
 
Negative Predictive Value : “The probability that a person who has tested 
negative on a diagnostic test (T−) actually does not have the disease (D−)” 
 
Positive Predictive Value : “This is the probability that a person who has tested 
positive on a diagnostic test (T+) actually has the disease(D+)”.  
 
Sensitivity : “This is the probability that a person with disease (D+) will 
correctly test positive based on the diagnostic test (T+)”  
 
Specificity: “This is the probability that a person without disease (D−) will 
correctly test negative based on the diagnostic test (T−)”  
 
D – Disease  ., T – Test 
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CONCLUSION  
 
For many decades Light’s criteria had been used widely to differentiate 
exudative from transudative pleural effusion. But it also misclassified 25 % of 
transudates as exudates, so there was a need to identify new parameters which 
would prove to be superior or supportive to the array of tests at present. 
From our study we came to known that there was no statistically 
significant difference among various criteria in classifying pleural effusion as 
exudates and transudates. 
The misclassification of exudates and transudates by various criteria 
when compared to Light’s criteria is not statistically significant as p value is 
<0.05. 
 
From our study we came to a conclusion that to classify an exudative 
pleural effusion from a transudative pleural effusion  
- most specific test is pleural fluid total protein and  
- most sensitive test is pleural fluid / serum alkaline phosphatase 
ratio .  
The “positive predictive value, negative predictive value and diagnostic 
accuracy is higher for pleural fluid total protein”. 
 
To conclude, “though Light's criteria remains as gold standard to 
differentiate transudates and exudates, in cases where there is a mismatch 
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between clinical diagnosis and the outcome from Light's criteria, pleural fluid 
alkaline phosphatase / serum alkaline phosphatase ratio and pleural fluid total 
protein evaluation may add to the diagnostic accuracy”.  
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SUMMARY  
 
The classic criteria of differentiating an exudate from a transudate is 
Light’s criteria. Over the last few years, “it has been noted that even Light's 
criteria may misclassify a significant percentage of pleural effusions.”  
“The objective of the present study was to evaluate the usefulness of 
Total Pleural fluid Alkaline phosphatase and its ratio to serum levels and Pleural 
fluid Total Protein level in classifying pleural effusions as exudates and 
transudates  with Light’s criteria as the gold standard “. 
From our study it is evident that most specific test to classify an 
exudative pleural effusion from a transudative pleural effusion is pleural fluid 
total protein which is 95.45 %  and most sensitive test is pleural fluid / serum 
alkaline phosphatase ratio which is 93.90 %. “The positive predictive value, 
negative predictive value and diagnostic accuracy is higher for pleural fluid total 
protein  which are 96.29 % , 95.23 % , 94 %  respectively”. 
“The sensitivity , specificity , positive predictive value, negative predictive 
value and diagnostic accuracy of  pleural fluid alkaline phosphatase was not 
superior to Light ‘s criteria” . 
 The pleural fluid/serum alkaline phosphatase ratio, pleural fluid total 
protein are very effective in differentiating exudative and transudative pleural 
effusion. 
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Limitations of the study  
1. Shorter study period and smaller study sample. 
2. The various parameters studied are neither combined with others nor 
with the Light’s criteria . 
3. Different levels of the “Pleural fluid alkaline phosphatase , Pleural 
fluid  / Serum alkaline phosphatase ratio, Pleural fluid total protein are 
not tried in this study” . 
 
Further recommendations  
1. “A longer study period and a larger study sample should be considered in the 
future”. 
2. “Combination of Pleural fluid alkaline phosphatase, Pleural fluid  / Serum 
Alkaline phosphatase ratio, Pleural fluid total protein with other parameters of 
the Light’s criteria”. 
3. “Another study on varying levels of Pleural fluid Alkaline phosphatase, 
Pleural fluid  / Serum Alkaline phosphatase ratio, Pleural fluid total protein 
which will give the highest accuracy in detecting exudative effusions”. 
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PROFORMA 
Name :     Age/Sex/Occupation: 
Presenting complaints: 
H/o Fever, chest pain , cough & expectoration, hemoptysis ,dyspnea, Loss of 
weight, Loss of Appetite. Etc. 
Past history: 
H/o Tuberculosis, Chronic liver disease, coronary artery disease, chronic kidney 
disease 
Clinical examination: 
General examination: 
Consciousness, Pallor, jaundice, Clubbing, Lymphadenopathy,  
Vitals: PR, BP, RR, SpO2, Temperature 
Systemic examination:  
CVS: 
 RS:  
Abdomen : 
 CNS: 
LABORATORY INVESTIGATIONS : 
1.Pleural fluid alkaline phosphatase & serum alkaline phosphatase  
3.Pleural fluid total protein & Serum Protein 
4.Pleural fluid LDH & Serum LDH 
 
S.No NAME AGE SEX DIAGNOSIS
PLEURAL 
FLUID 
PROTEIN 
g/ dl
SERUM 
PROTEI
N g/dl
PLEURAL 
FLUID 
PROTEIN / 
SERUM 
PROTEIN 
RATIO
PLEURA
L FLUID 
LDH
SERUM 
LDH
PLEURA
L FLUID 
/ SERUM 
LDH 
RATIO
PLEURA
L FLUID 
ALKAL 
INE  
PHOSPH
ATASE 
Ratio
1     45 M CCF 2.7 6.1 0.44 156 306 0.51 30 0.21
2 PANDIARAJAN 46 M CCF 2.9 5.6 0.51 132 288 0.45 35 0.25
3 IYYAMMAL 43 F CCF 2.9 6.4 0.45 45 159 0.28 36 0.26
4 AYYAVU 52 M CCF 2.5 6.2 0.4 116 250 0.46 38 0.27
5 LAKSHMANAN 62 M CCF 2.3 6.4 0.35 129 296 0.43 40 0.29
6 CHANDRAN 57 M CCF 2.9 6.5 0.44 112 220 0.51 42 0.30
7 KANAGA VALLI 55 F CCF 2.2 6.5 0.34 28 91 0.31 42 0.30
8 JAMUNA 53 F CCF 2.6 6.2 0.42 59 146 0.4 46 0.33
9 SELVA RANI 49 F CCF 2.8 5.2 0.53 98 189 0.51 38 0.27
10 NEHRU 65 M CCF 2.6 6.1 0.42 57 110 0.51 40 0.29
11 BAGHAYA LAKSHMI 57 F
Hepatic 
hydrothorax
2.9 6.4 0.45 69 156 0.44 30 0.21
12 MUTHU MANI 38 M
Hepatic 
hydrothorax
2.8 6.5 0.43 116 216 0.53 38 0.27
13 JAYA LAKSHMI 63 F
Hepatic 
hydrothorax
3.2 6.5 0.49 97 193 0.5 36 0.26
14 SIVA SANKARI 49 F
Hepatic 
hydrothorax
2.6 6.7 0.38 149 320 0.46 34 0.24
15 BASHEER AHMEED 57 M
Hepatic 
hydrothorax
2.3 6.4 0.35 133 287 0.46 35 0.25
16 MANIKANDAN 58 M
Hepatic 
hydrothorax
2.6 5.9 0.44 41 142 0.28 36 0.26
17 IRULAYI 35 F
Hepatic 
hydrothorax
2.6 5.8 0.43 26 98 0.26 40 0.29
18 MARI MUTHU 63 M
Hepatic 
hydrothorax
2.5 5.7 0.44 35 116 0.31 46 0.33
19 SONAI MUTHU 59 M CKD 2.5 5.9 0.45 19 85 0.22 41 0.29
20 ARJUNAN 60 M CKD 2.1 6.5 0.31 56 132 0.42 40 0.29
21 ANGARYARKANNI 55 F CKD 2.1 6.6 0.32 48 124 0.38 46 0.33
22 ESHWAR LAL 65 M CKD 2.3 6.7 0.34 38 106 0.35 38 0.27
23 RAJAMMAL 63 F Tuberculosis 3.8 6.1 0.62 79 165 0.47 60 0.43
24 PONAMBALAM 59 M Tuberculosis 3.5 6.1 0.39 100 133 0.38 65 0.46
25 RAGHAVAN 54 M Tuberculosis 4.4 6.1 0.72 45 95 0.47 62 0.44
26 MALAIKANI 64 M Tuberculosis 3.2 5.9 0.54 106 190 0.55 63 0.45
27 JAYAKUMAR 21 M Tuberculosis 3.6 6.1 0.59 98 172 0.56 78 0.56
28 PREMAVATHI 52 F Tuberculosis 3.2 5.6 0.57 94 166 0.56 70 0.50
29 RAJENDRAN 56 M Tuberculosis 3.3 5.5 0.6 69 124 0.55 76 0.54
30 GURUVAMMAL 53 F Tuberculosis 4.1 5.9 0.69 71 137 0.51 75 0.54
31 KUMAR 25 M Tuberculosis 3.2 6.8 0.43 58 101 0.42 74 0.53
32 RAMESH 65 M Tuberculosis 3.1 5.2 0.59 66 86 0.76 68 0.49
33 PANJU 68 F Tuberculosis 3.9 5.9 0.66 298 387 0.77 64 0.46
34 PALANIVEL 60 M Tuberculosis 3.6 5.3 0.67 250 320 0.78 82 0.59
35 MEENAKSHI 61 F Tuberculosis 4.1 6.1 0.65 114 235 0.48 80 0.57
36 RANJITHAM 30 F Tuberculosis 3.1 6.4 0.43 99 219 0.45 83 0.59
37 ARUMUGAM 32 M Pneumonia 3.5 6.5 0.53 306 421 0.72 84 0.60
38 GANESAN 57 M Pneumonia 3.2 6.6 0.42 112 216 0.4 86 0.61
39 VIMALA 36 F Pneumonia 3.4 6.1 0.56 341 487 0.71 84 0.60
40 SUMATHI 52 F Pneumonia 2.9 6.5 0.58 221 362 0.61 78 0.56
41 KANNAN 52 M Malignancy 3.2 5.9 0.54 74 116 0.63 68 0.49
42 SANTHA RAM 60 M Malignancy 3.1 5.8 0.53 102 154 0.66 64 0.46
43 VASANTHA 39 M Malignancy 2.7 5.9 0.42 82 198 0.41 85 0.61
44 INDRA 68 F Malignancy 3.4 6.3 0.53 68 85 0.79 65 0.46
45 KASIRAJAN 75 M Malignancy 3.3 6.1 0.54 41 79 0.51 64 0.46
46 THAVAMANI 47 F Malignancy 3.1 5.9 0.52 95 166 0.57 63 0.45
47 MYTHILI 52 F Malignancy 3.2 5.8 0.54 86 109 0.78 64 0.46
48 VASUDEVAN 49 M Malignancy 3.5 5.6 0.62 56 141 0.39 78 0.56
49 NARAYANAN 62 M Malignancy 3.2 5.8 0.43 112 163 0.42 78 0.56
50 KALAISELVI 67 F Malignancy 3.4 6.2 0.54 59 92 0.64 64 0.46
51 MARI MUTHU 63 M
Hepatic 
hydrothorax
2.5 5.7 0.44 35 116 0.31 46 0.33
52 SONAI MUTHU 59 M CKD 2.5 5.9 0.45 19 85 0.22 48 0.34
53 ARJUNAN 60 M CKD 2.1 6.5 0.31 56 132 0.42 45 0.32
54 ANGARYARKANNI 55 F CKD 2.1 6.6 0.32 48 124 0.38 72 0.51
55 ESHWAR LAL 65 M CKD 2.3 6.7 0.34 38 106 0.35 48 0.34
56 PANJU 68 F Tuberculosis 3.9 5.9 0.66 298 387 0.77 68 0.49
57 PALANIVEL 60 M Tuberculosis 3.6 5.3 0.67 250 320 0.78 70 0.50
58 MEENAKSHI 61 F Tuberculosis 4.1 6.1 0.65 114 235 0.48 72 0.51
59 RANJITHAM 30 F Tuberculosis 3.1 6.4 0.41 99 219 0.44 76 0.54
60 ARUMUGAM 32 M Pneumonia 3.5 6.5 0.53 306 421 0.72 78 0.56
3.03 6.11 0.49 105.40 191.57 0.50 58.25 0.42
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